Envoy Medical Inc. (Class A) (COCH) Options Positioning, Max Pain & Unusual Sweeps

Per the Roarable RQD rating, COCH carries an RQD Score of 35 out of 100 and a letter grade of D-, with the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are scored as follows:

• Fundamental Cash Engine: 7 / 20. The source cites ROIC of -35% and an FCF yield of 0%. For a prospective investor, this indicates the business is not currently generating a return on invested capital or free cash flow to offset its operating losses.
• Whale 13F Flow: 7 / 20. The pillar reflects institutional accumulation and options positioning. The underlying holder-level detail is not available in source data, so the weak score cannot be decomposed further.
• Insider Conviction: 5 / 20. This is the lowest pillar and reflects SEC Form 4 and Congressional PTR cluster flow. The individual transactions are not itemized in the source data.
• Macro Regime Fit: 8 / 20. Beta is 1.0, and the pillar also reflects sector sensitivity. A beta of 1.0 means the stock is modeled to move in line with the broad market, offering no defensive cushion.
• Forensic Balance Sheet: 8 / 20. Per the source, the Altman Z-Score is 2.5, the Piotroski F-Score is 2 out of 9, and Debt/Equity is 0.5. A low Piotroski score points to weak financial-health signals across multiple tests.

Taken together, the pillar scores point to a company with negative economics, weak forensic signals, and limited evidence of institutional or insider conviction. Upside drivers would need to come from a sustained change in operating results, which the historical financials do not yet show. The valuation tradeoff is that the market is pricing a small-cap, loss-making issuer, and the rating frames the risk as balance-sheet and flow vulnerability rather than a near-term earnings recovery. This analysis is educational and is not personalized financial advice.

Per the SEC financials, revenue has been minimal across the three reported years ($0.3M, then $0.2M in each of the two subsequent years), while operating losses and free-cash-flow burn have persisted. Per the market data, gross margin is -30%, operating margin is -60%, and net margin is -60%, with ROIC at -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2 out of 9, per the Roarable RQD rating. Cash and debt balances are not available in source data, so the balance-sheet posture can only be assessed through the Debt/Equity ratio of 0.5 cited in the forensic pillar.

Per the recent news and catalysts section, the most prominent items are:

• Initiation coverage: Lake Street initiated coverage at a buy rating on the company's cochlear device.
• Reverse stock split: The company announced a 1-for-10 reverse split effective October 26, which the reporting describes as intended to help meet Nasdaq's $1 minimum bid requirement. Share-price weakness was also noted in one headline.
• Scheduled call: The company will host a call at 4:30 p.m. ET on November 5 following its third-quarter results.

All six items are tagged as YELLOW light signals under the MARKET WIRE impact label. Risk watch items include the reverse split's implications for the share count and the need to satisfy the Nasdaq minimum bid requirement. The butterfly supply-chain graph reports no proprietary signals.

• What are the company's products, customers, and revenue model, given that the source does not describe the business beyond its sector classification?
• What are the reported cash and debt balances, which are listed as N/A across all periods?
• What drove the sharp swing in FY 2023 net income relative to operating income, and what is the source of the difference?
• What is the company's path to positive operating cash flow, and what funding is available to sustain the current burn rate?
• What would the post-reverse-split share count and per-share metrics look like, and how will they affect EPS and market-cap comparisons?